[Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome].

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation (BMT) with unrelated donor for myelodysplastic syndrome.

METHODS:

Six patients received chemotherapy regimen of busulfan (Bu) and cyclophosphamide (CY) before allogeneic BMT (Bu 4 mg . kg(-1) . d(-1), -7 d - -4 d, CY 60 mg . kg(-1) . d(-1), -3 d - -2 d). Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation. Lipo prostaglandin E(1)was used in prophylactic regimen for hepatic veno-occlusive disease.

RESULT:

Neutrophil count began to be higher than 0.5 x 10(9)/Lat the 18th day after BMT. Platelet count began to be higher than 20 x 10(9)/Lat the 21st day after BMT. Disease-free survival in the six patients was 27 months.

CONCLUSION:

Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation with unrelated donor is an effective therapy for patients with myelodysplastic syndrome.

• Authors: Ji-min Shi, He Huang, Zhen Cai, Yi Luo, Xiu-jin Ye, Jie Zhang, Li Li, Jing-song He, Wan-zhuo Xie, Wei-yan Zheng, Xiao-jian Meng, Mao-fang Lin
• Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences (Zhejiang Da Xue Xue Bao Yi Xue Ban) Vol. 35 Issue 2 Pg. 122-6 (03 2006) ISSN: 1008-9292 [Print] China
• PMID: 16610075 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclophosphamide
• Busulfan

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Marrow Transplantation
• Busulfan (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Male
• Myelodysplastic Syndromes (surgery)
• Transplantation Conditioning